Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4MDJY)

Drug Name
Fluvastatin Drug Info
Synonyms
Canef; Cranoc; Fluindostatin; Fluvas; Fluvastatina; Fluvastatine; Fluvastatinum; Lescol; Lescol XL; XU 62320; Canef(TN); Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina [INN-Spanish]; Fluvastatine [INN-French]; Fluvastatinum [INN-Latin]; Lescol (TN); Vastin (TN); XU-62320; (+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Therapeutic ClassAnticholesteremic Agents
Cross-matching ID
PubChem CID
446155
ChEBI ID
CHEMBL38565
CAS Number
CAS 93957-54-1
TTD Drug ID
D08GHB
VARIDT Drug ID
DR00124
INTEDE Drug ID
DR0738
ACDINA Drug ID
D00289

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.42 0.00e+0 19/20 (95%) NSDHL;SQLE;EBP;...
Biosynthesis of unsaturated fatty acids 2.26 0.00e+0 21/27 (77.78%) SCD;ELOVL6;FADS1;...
Steroid hormone biosynthesis 2.14 3.13e-3 43/61 (70.49%) HSD17B7;AKR1C2;AKR1C1;...
Metabolism of xenobiotics by cytochrome P450 2.08 4.70e-3 49/77 (63.64%) AKR1C1;EPHX1;CYP1B1;...
PPAR signaling pathway 2.03 5.64e-3 66/74 (89.19%) SCD;FADS2;ACSL1;...
Cholesterol metabolism 1.98 6.26e-3 44/50 (88%) LDLR;NPC1;LIPA;...
Glycerolipid metabolism 1.94 6.71e-3 44/61 (72.13%) MGLL;LPIN1;PNPLA3;...
Terpenoid backbone biosynthesis 1.92 9.40e-3 18/22 (81.82%) HMGCR;ACAT2;IDI1;...
AMPK signaling pathway 1.83 1.36e-2 106/120 (88.33%) SCD;HMGCR;FASN;...
Ovarian steroidogenesis 1.82 1.79e-2 41/51 (80.39%) HSD17B7;LDLR;AKR1C3;...
Fatty acid elongation 1.81 1.88e-2 19/27 (70.37%) ELOVL6;ELOVL5;ACOT7;...
Phosphatidylinositol signaling system 1.79 2.11e-2 82/97 (84.54%) PIK3R3;CALML4;CALML5;...
Primary bile acid biosynthesis 1.78 2.31e-2 15/17 (88.24%) HSD17B4;AMACR;AKR1D1;...
Peroxisome 1.77 2.21e-2 72/82 (87.8%) IDH1;ACSL1;ECH1;...
Glutathione metabolism 1.73 3.32e-2 43/57 (75.44%) IDH1;PGD;GPX2;...
Fatty acid biosynthesis 1.72 3.41e-2 16/18 (88.89%) FASN;ACSL1;ACACA;...
Fat digestion and absorption 1.71 3.70e-2 35/43 (81.4%) ACAT2;PLPP3;PLPP2;...
Phototransduction 1.71 3.50e-2 21/29 (72.41%) CALML4;CALML5;CALML3
Pentose phosphate pathway 1.70 3.81e-2 25/30 (83.33%) ALDOC;PGD;G6PD;...
Axon guidance 1.66 4.89e-2 151/182 (82.97%) PIK3R3;EPHA3;ABLIM3;...
Systemic lupus erythematosus -1.71 3.60e-2 45/135 (33.33%) CD86;TRIM21;SNRPB;...
Asthma -1.71 3.93e-2 25/31 (80.65%) IL3;FCER1A;HLA-DMB;...
Type I diabetes mellitus -1.78 1.62e-2 38/43 (88.37%) CD86;HLA-DRB1;LTA;...
Allograft rejection -1.80 1.56e-2 32/38 (84.21%) HLA-DMB;CD28;CD40LG;...
Cell cycle -1.80 1.76e-2 110/124 (88.71%) CDC23;CCNH;ORC5;...
Proteasome -1.81 1.54e-2 44/46 (95.65%) PSMD12;PSMD9;POMP;...
Inflammatory bowel disease -1.83 1.80e-2 58/65 (89.23%) STAT3;IL1A;HLA-DOB;...
Spliceosome -1.91 6.49e-3 101/150 (67.33%) RBMX;THOC1;MAGOHB;...
RNA polymerase -1.96 8.11e-3 23/31 (74.19%) POLR3K;POLR3E;POLR2E;...
DNA replication -2.15 3.60e-3 34/36 (94.44%) RNASEH1;RPA2;RFC5;...
Ribosome biogenesis in eukaryotes -2.34 0.00e+0 52/108 (48.15%) RAN;TBL3;RPP38;...
RNA transport -2.37 0.00e+0 128/186 (68.82%) EIF3G;EIF2S2;RAN;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.11uM - 10uM 6H, 24H